
Original articleA double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis
Keywords: adalimumab; efficacy; safety; sarcoidosis; treatment; tumor necrosis factor; AE; adverse event(s); DLQI; Dermatology Life Quality Index; FEV1; forced expiratory volume in one second; FVC; forced vital capacity; PGA; Physician Global Assessment; PGE; Patie